PROTALIX BIOTHERAPEUTICS INC (PLX)
Health Care · Rare disease biopharmaceuticals / enzyme replacement therapy · NYSE American
A rare-disease biopharmaceutical company with a proprietary plant cell-based protein expression platform and two FDA/EMA-approved enzyme replacement therapies for lysosomal storage disorders.
What PROTALIX BIOTHERAPEUTICS INC does
Protalix Biotherapeutics is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for rare and orphan diseases. It operates a proprietary ProCellEx plant cell-based protein expression system, the first and only platform to achieve FDA approval for proteins produced through plant cell suspension culture. The company currently markets two enzyme replacement therapies (ERTs): Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease, while developing new candidates including PRX-115 (PEGylated uricase) for gout and PRX-119 (LA DNase I) for NET-related diseases.
Themes: Enzyme replacement therapy / lysosomal storage disorders, Rare and orphan diseases, Plant-based biotherapeutics / recombinant protein production, Gaucher disease, Fabry disease, Gout treatment, Protein modification / PEGylation
Fundamentals
- Price$2.38 as of 2026-08-21 close
- Market cap$192M as of 2026-08-21
- 1-year return+50.6% 2025-08-21 close $1.58 → 2026-08-21 close $2.38
- P/E12.40 as of 2026-08-24
- Net margin+20.1% as of 2026-08-24
- Gross margin+70.0% as of 2026-08-24
- ROE+28.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+27.8% as of 2026-08-24
- Revenue CAGR (3y)+3.5% SEC XBRL
- Beta-0.11 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How PLX compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PROTALIX BIOTHERAPEUTICS INC looks technically
PROTALIX BIOTHERAPEUTICS INC (PLX) is trading 7.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 14 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It made a new 20-day low about 6 trading days ago. It is 25.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 7.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.31 | $2.31 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.22 | $2.22 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 14 trading days ago — a "golden cross", a bullish long-term signal | 14 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 7.1% above | +7.1% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 25.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 51, neither overbought (above 70) nor oversold (below 30) | 51.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($2.17 to $2.71) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 39.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.19 | $3.19 |
|---|---|---|
| From the 52-week high | it is 25.4% below its 52-week high (its highest price of the past year) | -25.4% |
| Above the 52-week low | it is 60.8% above its 52-week low (its lowest price of the past year) | +60.8% |
| Below the 52-week high | it is 25.4% below its highest point of the past year | 25.4% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $912.50 (set on 1998-05-18) | $912.50 |
| Given back of the 52-week move | over the past year its closes ranged ($1.54 to $3.15), and it has given back around half of its rise from last year’s low — 48% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.10 to $2.15. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 47.8% |
| From the all-time high | it is 99.7% below its all-time high | -99.7% |
| Nearest price level | it is sitting right on a support level at $2.38 — a price it turned at twice since 2025-01-06, most recently on 2026-04-15. Since 2024-08-21 it has 10 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.2% |
| All-time low | its lowest closing price on record is $0.7 (set on 2022-02-24) | $0.7 |
| Above the all-time low | it is 240.0% above its all-time low | +240.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 32nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1153 between its high and its low — about 4.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1153 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.20 and $2.55 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.20 – $2.38 – $2.55 |
| Typical daily range (% of price) | its price moves about 4.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.8% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges above its 200-day average price (7.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
3
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Gap filled | a 2.5% gap up opened on 2026-08-12 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 7 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.5 percentage points (the stock gained 0.8% while the market gained 2.3%) | -1.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 14.1 percentage points (the stock gained 17.2% while the market gained 3.1%) | +14.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 33.3 percentage points (the stock lost 22.2% while the market gained 11.1%) | -33.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 30.2 percentage points (the stock gained 50.6% while the market gained 20.5%) | +30.1% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.7% of the share price. | +3.8% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.39 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -0.6% |
|---|
Price levels it has turned at before
PLX last closed at $2.38 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.38 | Support | 0.2% below the last close | turned there twice · 2025-01-06 to 2026-04-15 |
| $2.46 | Resistance | 3.6% above the last close | turned there twice · 2025-10-27 to 2026-07-13 |
| $2.19 | Support | 8.2% below the last close | turned there five times · 2025-02-28 to 2026-08-14 |
| $2.13 | Support | 10.6% below the last close | turned there five times · 2025-01-14 to 2026-04-23 |
| $2.66 | Resistance | 11.8% above the last close | turned there twice · 2025-03-24 to 2025-10-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$11.00 range $10.00 – $12.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Dependence on partner commercialization: Elelyso revenues depend on Pfizer and Fiocruz order patterns, which may vary period-to-period and lack direct correlation to patient demand, creating revenue volatility.","Regulatory and clinical risk: Early-stage pipeline candidates (PRX-115, PRX-119) require successful Phase 2 and potentially Phase 3 trials and regulatory approval before generating meaningful revenue.","Limited market for approved products: Gaucher disease and Fabry disease are rare conditions with limited patient populations, constraining market size despite high disease burden."]
What changed in the latest 10-Q
AI-assisted comparison of PLX's 10-Q filed 2026-05-13 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 'Annual Report on Form 10-K for the year ended December 31, 2025' (newer filing, filed 2026-05-13)
- Addition of Iran regional conflict and Houthi terrorist group to geopolitical risk discussion: 'the regional conflict in Iran and the military actions between Israel and Iran, the Hamas terrorist organization located in the Gaza Strip, Hezbollah, the Houthis terrorist group that controls parts of Yemen, and others' (newer filing, filed 2026-05-13)
- Addition of specific clause regarding Fiocruz: 'Fundação Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MoH' (newer filing, filed 2026-05-13)
- Addition of 'new or changed' modifying trade restrictions: 'new or increased tariffs, new or changed trade restrictions' (newer filing, filed 2026-05-13)
- Addition of phrase 'the risk that' preceding clinical trial results language: 'the risk that the results of the clinical trials of our product candidates will not support' (newer filing, filed 2026-05-13)
- Removed:
- Reference to 'Annual Report on Form 10-K for the year ended December 31, 2024' (older filing, filed 2025-11-13)
- Clause regarding CHMP re-examination: 'including the requested a re-examination of the negative opinion issued by the CHMP regarding the proposed dosing regimen of 2 mg/kg body weight infused E4W for Elfabrio' (older filing, filed 2025-11-13)
- Phrase 'and/or lack of sufficient funding to finance our clinical trials' from clinical trial risk (older filing, filed 2025-11-13)
- Section titled 'Recent Company Developments' with entries about August 24, 2025 CFO succession and October 6, 2025 IND application submission (older filing, filed 2025-11-13)
- Language about 'greater regional conflict' replaced with 'increased regional conflict' (older filing, filed 2025-11-13)
- Reworded:
- Changed 'reimbursement and regulatory actions' to 'reimbursement, and regulatory actions' (addition of comma, newer filing)
- Changed description of geopolitical risk from 'military actions conducted by Israel with the Hamas terrorist organization' to 'military actions between Israel and Iran' and expanded scope (newer filing, filed 2026-05-13)
- Changed 'the risk that the current hostilities will result in a greater regional conflict' to 'the risk that the current hostilities will result in increased regional conflict' (newer filing, filed 2026-05-13)
- Reordered bullet points: moved regulatory approval risk before expectations/market risk (newer filing)
- Changed 'our cash and cash equivalents and short-term bank deposits' to 'our cash, cash equivalents, and short-term bank deposits' (addition of commas, newer filing)
- Changed 'collaborators, distributors or partners' to 'collaborators, distributors, and partners' (addition of serial comma, newer filing)
- Changed 'Fiocruz' to include full name and acronym detail: 'Fundação Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MoH' (newer filing)
- Notes:
- Newer filing is truncated at 'comm' and does not include 'Recent Company Developments' section or 'Our Business' section completion, making full comparison of those sections not assessable
- Older filing text is also truncated starting at 'October 17' in the Recent Company Developments section
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2025-12-19. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PLX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PLX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,887,082
- Reported value $12,774,968
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PLX had 3,878,764 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PLX had 4.81% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.46 days to cover at the same settlement.
- Reported short interest (shares) 3,878,764
- Short interest (% of shares outstanding) 4.81%
- Prior settlement (shares) 3,715,907
- Reported change 4.38%
- Days to cover (reported) 7.46
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNYNFSMR) - markets Imiglucerase for Gaucher disease
- Genzyme Corporation (subsidiary of Sanofi) - alternative Gaucher treatments
- Amylyx Pharmaceuticals - rare disease focus
- Alexion / AstraZeneca - rare disease therapies
- Sangamo Therapeutics - rare disease gene therapy
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PLX vs…
Frequently asked questions
What does PROTALIX BIOTHERAPEUTICS INC (PLX) do?
Protalix Biotherapeutics is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for rare and orphan diseases. It operates a proprietary ProCellEx plant cell-based protein expression system, the first and only platform to achieve FDA approval for proteins produced through plant cell suspension culture.
What sector is PROTALIX BIOTHERAPEUTICS INC (PLX) in?
PROTALIX BIOTHERAPEUTICS INC (PLX) is classified in the Health Care sector. Its industry is Rare disease biopharmaceuticals / enzyme replacement therapy. It trades on NYSE American.
Who are PROTALIX BIOTHERAPEUTICS INC's (PLX) competitors?
Notable peers of PROTALIX BIOTHERAPEUTICS INC (PLX) include Sanofi (SNYNFSMR) - markets Imiglucerase for Gaucher disease, Genzyme Corporation (subsidiary of Sanofi) - alternative Gaucher treatments, Amylyx Pharmaceuticals - rare disease focus, Alexion / AstraZeneca - rare disease therapies and Sangamo Therapeutics - rare disease gene therapy. This peer set is informational only — not financial advice.
Is PROTALIX BIOTHERAPEUTICS INC (PLX) overbought or oversold right now?
PROTALIX BIOTHERAPEUTICS INC (PLX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 51, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PLX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.